AstraZeneca Shares Drop Amid Conflicting Merger Reports
AstraZeneca PLC and Bristol Myers Squibb Company reportedly held preliminary merger talks, though the companies declined to comment and some reports deny active negotiations.
Reports surfaced on August 5 regarding potential merger discussions between AstraZeneca PLC and Bristol Myers Squibb Company. The companies have refused to comment on the status of these preliminary talks, and accounts of the situation remain conflicting. While some reports indicate discussions occurred, Reuters stated that no active talks are currently taking place.
Investor reaction following the news was negative. AstraZeneca PLC shares fell 9%, while shares of Bristol Myers Squibb Company remained flat. Analysts have questioned the strategic logic of such a deal, citing AstraZeneca PLC's growth potential in contrast to the projected earnings per share shrinkage at Bristol Myers Squibb Company.
Keep reading in the app
The full story and every source, free in the app.
Coming soonGoogle Play